ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,870.62
      -1.32%
      US Tech 100
      19,880.00
      -2.30%
      Dow Jones
      43,444.99
      -0.70%
      Brent Oil
      71.25
      0.50%
      Bitcoin
      90,578.89
      -0.53%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Zentalis Pharmaceuticals Inc (ZNTL) Quote

      Zentalis Pharmaceuticals Inc

      Zentalis Pharmaceuticals Inc (ZNTL)

      NASDAQ
      3.47
      -0.48
      (-12.15%)
      Closed November 16 4:00PM
      Delayed by 15 minutes
      3.47
      0.00
      (0.00%)
      After Hours: 6:55PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      3.47
      Bid
      3.50
      Ask
      3.93
      Volume
      1,799,202
      3.36 Day's Range 3.97
      2.66 52 Week Range 18.07
      Market Cap
      246.745M
      Previous Close
      3.95
      Open
      3.97
      Last Trade
      5
      @
      3.4
      Last Trade Time
      Financial Volume
      $ 6,281,911
      VWAP
      3.4915
      Average Volume (3m)
      2,129,584
      Shares Outstanding
      71,107,967
      Dividend Yield
      -
      PE Ratio
      -0.84
      Earnings Per Share (EPS)
      -4.11
      Revenue
      -
      Net Profit
      -292.19M

      About Zentalis Pharmaceuticals Inc

      Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets a... Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.zentalis.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Zentalis Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZNTL. The last closing price for Zentalis Pharmaceuticals was $3.95. Over the last year, Zentalis Pharmaceuticals shares have traded in a share price range of $ 2.66 to $ 18.07.

      Zentalis Pharmaceuticals currently has 71,107,967 shares outstanding. The market capitalization of Zentalis Pharmaceuticals is $280.88 million. Zentalis Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.84.

      Ask ADVFN Intelligence (AI)

      ZNTL Latest News

      More News

      Form 3 - Initial statement of beneficial ownership of securities

      November 13 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 13 2024
      Edgar (US Regulatory)

      Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib

      Julie Eastland appointed Chief Executive Officer, President and Director Ingmar Bruns, M.D., appointed Chief Medical Officer Scott Myers appointed to the Board of Directors as Chairperson SAN...

      November 13 2024
      GlobeNewswire Inc.

      Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small...

      November 01 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      October 04 2024
      Edgar (US Regulatory)

      Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

      Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, Sept. 16, 2024 NEW YORK, Sept. 16, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...

      September 16 2024
      PR Newswire (US)

      Form 8-K - Current report

      September 16 2024
      Edgar (US Regulatory)

      Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

      SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

      September 16 2024
      GlobeNewswire Inc.

      Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

      SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

      September 09 2024
      GlobeNewswire Inc.

      Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated...

      September 03 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.38-9.870129870133.854.443.4714673043.92879318CS
      40.4816.05351170572.994.442.6615646723.38779525CS
      120.4113.39869281053.065.442.6621295843.57319335CS
      26-8.74-71.580671580712.21132.6617137024.26226469CS
      52-8.28-70.468085106411.7518.072.6612615557.14735527CS
      156-74.3-95.538125241177.7785.952.6686743617.1558028CS
      260-21.22-85.94572701524.6987.192.6665366421.70760056CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CEROCERo Therapeutics Holdings Inc
      $ 0.2853
      (52.40%)
      		1.17B
      CYCNCyclerion Therapeutics Inc
      $ 2.5306
      (42.97%)
      		11.99M
      SPPLSIMPPLE Ltd
      $ 1.2503
      (41.60%)
      		165.69M
      PULMPulmatrix Inc
      $ 6.5586
      (39.54%)
      		5.37M
      ZTEKZentek Ltd
      $ 1.2574
      (29.96%)
      		309.67k
      TFFPTFF Pharmaceuticals Inc
      $ 0.376101
      (-76.49%)
      		9.35M
      EYENEyenovia Inc
      $ 0.10185
      (-70.05%)
      		52.8M
      CTXRCitius Pharmaceuticals Inc
      $ 0.1974
      (-39.89%)
      		11.26M
      VVPRVivoPower International PLC
      $ 0.8151
      (-39.62%)
      		2.34M
      IPWiPower Inc
      $ 0.7302
      (-39.15%)
      		1.15M
      CEROCERo Therapeutics Holdings Inc
      $ 0.2853
      (52.40%)
      		1.17B
      ELABElevai Labs Inc
      $ 0.0211
      (-19.47%)
      		380.03M
      NVDANVIDIA Corporation
      $ 141.98
      (-3.26%)
      		253.02M
      SPPLSIMPPLE Ltd
      $ 1.2503
      (41.60%)
      		165.69M
      STISolidion Technology Inc
      $ 0.44
      (25.71%)
      		140.02M

      ZNTL Discussion

      View Posts
      Awl416 Awl416 2 months ago
      Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
      👍️0
      glenn1919 glenn1919 2 months ago
      ZNTL.......................................https://stockcharts.com/h-sc/ui?s=ZNTL&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 2 months ago
      ZNTL under $4
      👍️0
      ANTADOG ANTADOG 4 years ago
      We managed to get a new 26 week high and a reset around 46 bucks, will be interesting to see where it goes next, chartwise it's up, imo of course, ANT
      👍️0
      ANTADOG ANTADOG 4 years ago
      Added some 46's , nice chart reset, ANT
      👍️0
      ANTADOG ANTADOG 4 years ago
      55.12~~ looks like this puppy is on it's way for a new 52 week high, my target here is 100 bucks because of the very promising pipeline , fyi imo ANT
      👍️0
      ANTADOG ANTADOG 4 years ago
      NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Ahmed Samatar, Ph.D., Senior Vice President of Oncology Research at Zentalis, will present preclinical data on ZN-c5 at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting II taking place June 22-24th.

      The preclinical data demonstrated that ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, had antitumor activity in human tumor breast cancer xenograft models. ZN-c5 also displayed excellent oral bioavailability across several preclinical species. ZN-c5 is currently being evaluated in a Phase 1/2 clinical trial in patients with ER+/HER2- advanced or metastatic breast cancer both as a single agent and in combination studies.
      👍️0
      ANTADOG ANTADOG 4 years ago
      NEW YORK and SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.
      fyi ANT
      👍️0
      ANTADOG ANTADOG 4 years ago
      New 52 week high at 52.09, i luv it, ANT
      👍️0
      ANTADOG ANTADOG 4 years ago
      Cash Position: As of March 31, 2020, Zentalis had cash and cash equivalents of $63.7 million. We expect that the Company’s existing cash and cash equivalents, together with the net proceeds of $172.4 million from the IPO, will enable the Company to fund its operating expenses and capital expenditure requirements into 2022.
      fyi ANT
      👍️0
      ANTADOG ANTADOG 4 years ago
      Chart is pretty fresh here, anyway, i see a trendline curlin' up already (10ma on the daily at 35.9), fyi ANT
      👍️0
      ANTADOG ANTADOG 5 years ago
      promisin' co, interestin' pipeline, touched new 52 week high today (42.83), enormous spread every now and then, fyi ANT
      👍️0
      crudeoil24 crudeoil24 5 years ago
      ZNTL opens @ 25.20 >
      👍️0
      crudeoil24 crudeoil24 5 years ago
      Zentalis Pharma Upsized IPO Prices at High End of Range >ZNTL
      6:08 am ET April 3, 2020 (Dow Jones) Print
      By Colin Kellaher

      Zentalis Pharmaceuticals Inc. said its upsized initial public offering of 9.18 million shares was priced at $18 each, the high end of the expected range.

      The New York clinical-stage cancer biopharmaceutical company earlier this week said it expected to sell 7.65 million shares at $16 to $18 apiece.

      Zentalis said it expects gross proceeds of $165.2 million from the IPO, adding that it has granted the underwriters an option to buy up to 1.38 million additional shares.

      Zentalis previously said it will use proceeds from the offering to advance the development of its drug candidates.

      Write to Colin Kellaher at colin.kellaher@wsj.com

      (END) Dow Jones Newswires

      April 03, 2020 06:08 ET (10:08 GMT)

      Copyright (c) 2020 Dow Jones & Company, Inc.
      👍️0
      crudeoil24 crudeoil24 5 years ago
      Zentalis Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
      👍️0

      Your Recent History

      NASDAQ
      ZNTL
      Zentalis Pharmaceuticals
      Delayed Upgrade Clock